On the dark side of therapies with immunoglobulin concentrates: The adverse events

Frontiers in Immunology

Volumn 6, Issue FEB, 2015, Pages

  Späth, Peter J ^a   Granata, Guido ^b   La Marra, Fabiola ^b   Kuijpers, Taco W ^c   Quinti, Isabella ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Adverse events; Complement; Cytokines; Hemolysis; IVIG; SCIG; Thrombosis

Indexed keywords

ALLOANTIBODY; ANAPHYLATOXIN; BLOOD GROUP A ANTIGEN; BLOOD GROUP B ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANAPHYLAXIS; ANOREXIA; ARTHRALGIA; ASEPTIC MENINGITIS; AUTOIMMUNE THROMBOCYTOPENIA; BACKACHE; BLOODSTREAM INFECTION; BRONCHOSPASM; CEREBROVASCULAR ACCIDENT; CHILL; COLITIS; CREUTZFELDT JAKOB DISEASE; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG INDUCED DISEASE; DRUG SAFETY; DYSESTHESIA; DYSPNEA; ECZEMA; ERYTHEMA MULTIFORME; FATIGUE; FEVER; FLU LIKE SYNDROME; FLUSHING; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; HYPERTENSION; HYPERVISCOSITY SYNDROME; HYPOTENSION; IMMUNE SYSTEM; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOGLOBULIN VARIABLE REGION; INJECTION SITE PAIN; ION EXCHANGE CHROMATOGRAPHY; KIDNEY FAILURE; MACULOPAPULAR RASH; MALAISE; MIGRAINE; MUSCLE CRAMP; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; PLEURA EFFUSION; PRURITUS; REVIEW; SUBSTITUTION THERAPY; SWELLING; TACHYCARDIA; THORAX PAIN; THROMBOSIS; TRANSFUSION RELATED ACUTE LUNG INJURY; URTICARIA; VASCULITIS; VIRAL CLEARANCE; VIRUS INACTIVATION; WEAKNESS;

EID: 84926649695     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00011     Document Type: Review

References (183)

1. John TJ, Ninan GT, John F, Flewett TH, Francis DP, Zuckerman DP. Epidemic hepatitis B caused by commercial human immunoglobulin. Lancet (1979) 1:1074. doi: 10.1016/S0140-6736(79)92964-7
2. Barandun S, Kistler P, Jeunet F, Isliker H. Intravenous administration of human γ-globulin. Vox Sang (1962) 7:157-74. doi:10.1111/j.1423-0410.1962.tb03240.x
3. Ellis EF, Henney CS. Adverse reactions following administration of human gamma-globulin. J Allergy (1969) 43:45-54. doi:10.1016/0021-8707(69)90019-7
4. Kamme C, Dahlquist E, Jonsson S, Lindström F. IgG antibodies to IgA in two patients with hypogammaglobulinemia treated with commercial gammaglobulin. Acta Pathol Microbiol Immunol Scand (1975) 83:189-94.
5. Alving BM, Tankersley DL, Mason BL, Rossi F, Aronson DL, Finlayson JS. Contact-activated factors: contaminants of immunoglobulin preparations with coagulant and vasoactive properties. J Lab Clin Med (1980) 96:334-46.
6. Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet (1986) 2:217-8. doi:10.1016/S0140-6736(86)92511-0
7. Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet (1992) 339:662-4. doi:10.1016/0140-6736(92)90806-E
8. Späth PJ, Van Holten RW, Kempf C. Pathogen safety of immunoglobulin preparations. 2nd ed. In: Wahn V, Orange J, editors. Clinical Use of Immunoglobulins. Bremen: UNI-MED Verlag (2013). p. 26-50.
9. Jackson GS, Burk-Rafel J, Edgeworth JA, Sicilia A, Abdilahi S, Korteweg J, et al. Population screening for variant Creutzfeldt-Jakob disease using a novel blood test: diagnostic accuracy and feasibility study. JAMA Neurol (2014) 71:421-8. doi:10.1001/jamaneurol.2013.6001
10. Kaveri SV. Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev (2012) 11:792-4. doi:10.1016/j.autrev.2012.02.006
11. Baumgarth N, Tung JW, Herzenberg LA. Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion. Springer Semin Immunopathol (2005) 26:347-62. doi:10.1007/s00281-004-0182-2
12. Terness P, Kohl I, Hubener G, Battistutta R, Moroder L, Welschof M, et al. The natural human IgG anti-F(ab')2 antibody recognizes a conformational IgG1 hinge epitope. J Immunol (1995) 154:6446-52.
13. Lutz HU, Fumia S. Stimulation of complement amplification by F(ab')2-containing immune complexes and naturally occurring anti-hinge antibodies-possible role in systemic inflammation. Autoimmunity (2008) 7:508-13. doi:10.1016/j.autrev.2008.04.017
14. Bouhlal H, Martinvalet D, Teillaud J-L, Fridman C, Kazatchkine MD, Bayry J, et al. Natural autoantibodies to Fcγ receptors in intravenous immunoglobulins. J Clin Immunol (2014) 34(Suppl 1):S4-11. doi:10.1007/s10875-014-0019-2
15. Bouhlal H, Kaveri S. Multi-faceted role of naturally occurring autoantibodies in fighting pathogens. Adv Exp Med Biol (2012) 750:100-13. doi:10.1007/978-1-4614-3461-0_8
16. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med (2001) 345:747-55. doi:10.1056/NEJMra993360
17. Negi VS, Elluru S, Sibéril S, Graff-Dubois S, Mouthon L, Kazatchkine MD, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol (2007) 27:233-45. doi:10.1007/s10875-007-9088-9
18. Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med (1951) 38:1-10.
19. Imbach P, Barandun S, D'Apuzzo V, Baumgartner C, Hirt A, Morell A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet (1981) 1:1228-31. doi:10.1016/S0140-6736(81)92400-4
20. Altznauer F, von Gunten S, Späth P, Simon HU. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J Allergy Clin Immunol (2003) 112:1185-90. doi:10.1016/j.jaci.2003.09.045
21. Casulli S, Topcu S, Fattoum L, von Gunten S, Simon HU, Teillaud JL, et al. A differential concentration-dependent effect of IVIg on neutrophil functions: Relevance for anti-microbial and anti-inflammatory mechanisms. PLoS ONE (2011) 6:e26469. doi:10.1371/journal.pone.0026469
22. Späth P, Kempf C, Gold R. Herstellung, Verträglichkeit und Virussicherheit von intravenösen Immunglobulinen. 1st ed. In: Berlit P, editor. Immunglobuline in der klinischen Neurologie. Darmstadt: Steinkopff (2001). p. 1-42.
23. Divan HA, Menis M, Sridhar G, Selvam N, Forshee R, Izurieta HS. Occurrence of hemolytic reactions (HRS) on the same day as immune globulin (IG) product administrations during 2008-2012 [abstract]. Pharmacoepidemiol Drug Saf (2013) 25:436. doi:10.1002/pds.3512
24. Min J, Bhatt A, Aburashed R, Burton S. Cerebral venous and sinus thrombosis associated with subcutaneous immunoglobulin injection and oral contraceptive use. Neurol Sci (2012) 33:627-9. doi:10.1007/s10072-011-0778-y
25. Moltenis M, Valnet Rabier M, Rohrlich P, Kantelip J. Multiple immunoglobulin intolerance without antibody's anti-immunoglobulin A: a case report [abstract]. Fundam Clin Pharmacol (2011) 25(Suppl 1):72. doi:10.1111/j.1472-8206.2011.00930.x
26. Thobani S, Hu E, Huynh P, Scott L. Common variable immunodeficiency: a patient with anaphylaxis to intravenous and subcutaneous immunoglobulin. J Allergy Clin Immunol (2010) 125:AB143. doi:10.1016/j.jaci.2009.12.559
27. Quinti I, Soresina A, Agostini C, Spadaro G, Matucci A, Sfika I, et al. Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration. J Clin Immunol (2008) 28:263-7. doi:10.1007/s10875-007-9169-9
28. Richard C, Michael B. Severe adverse reaction to subcutaneous immunoglobulin therapy in a patient with common variable immunodeficiency [abstract]. Clin Exp Immunol (2013) 174(Suppl 1):33. doi:10.1111/cei.12218
29. Zenker O, Rojavin M, Baggish J, Bexon M. Evaluation of the relationship between injection site reaction rate and SCIg doses in patients with primary immunodeficiencies. J Allergy Clin Immunol (2012) 129(2 Suppl1):AB194. doi:10.1016/j.jaci.2011.12.287
30. Barandun S, Morell A. Adverse reactions to immunoglobulin preparations. In: Nydegger UE, editor. Immunthemotherapy: A Guide to Immunoglobulin Prophylaxis and Therapy. London: Academic Press (1981). p. 223-7.
31. Björkander J, Wadsworth C, Hanson LA. 1040 Prophylactic infusions with an unmodified intravenous immunoglobullin product causing few side-effects in patients with antibody deficiency syndromes. Infect (1985) 13:102-10. doi:10.1007/BF01642867
32. Rachid R, Bonilla FA. The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. J Allergy Clin Immunol (2012) 129:628-34. doi:10.1016/j.jaci.2011.06.047
33. Lu P, Ling B, Li R. Prevalence of immunoglobulin a deficiency (IgAD) in Shanghai blood donors and efforts to establish a rare blood bank of IgAD in Shanghai [abstract]. Transfusion (2013) 53:98A-9A. doi:10.1111/trf.12401
34. IUIS Scientific Committee. Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. International Union of Immunological Societies. Clin Exp Immunol (1999) 118(Suppl 1):1-28. doi:10.1046/j.1365-2249.1999.00109.x
35. Hammarström L, Persson MAA, Smith CIE. Anti-IgA in selective IgA deficiency-in vitro effects and Ig subclass pattern of human anti-IgA. Scand J Immunol (1983) 18:509-13.
36. Björkander J, Hammarström L, Smith CI, Buckley RH, Cunningham-Rundles C, Hanson LA. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol (1987) 7:8-15. doi:10.1007/BF00915419
37. Ferreira A, Garcia Rodriguez MC, Fontán G. Follow-up of anti-IgA antibodies in primary immunodeficient patients treated with gamma-globulin. Vox Sang (1989) 56:218-22. doi:10.1111/j.1423-0410.1989.tb02032.x
38. Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia: detection of IgE antibodies to IgA. N Engl J Med (1986) 314:560-4. doi:10.1056/NEJM198602273140907
39. Tinegate HN, Ball J, Poles D, Regan F, Sewell C, Bolton-Maggs P. Management of immunoglobulin A deficiency: lessons from haemovigilance [abstract]. Vox Sang (2013) 105(S1):23. doi:10.1111/vox.12047
40. Palmer DS, O'Toole J, Montreuil T, Scalia V, Yi QL, Goldman M, et al. Screening of Canadian blood services donors for severe immunoglobulin A deficiency. Transfusion (2010) 50:1524-31. doi:10.1111/j.1537-2995.2010.02588.x
41. Ropars C, Müller A, Paint N, Beige D, Avenard G. Large scale detection of IgA deficient blood donors. J Immunol Methods (1982) 54:183-9. doi:10.1016/0022-1759(82)90059-X
42. Strobel E, von Meyer A. Unexpected reactions of the anti-IgA antibody particle gel immunoassay. Transfus Med (2014) 24:55-7. doi:10.1111/tme.12094
43. Robitaille N, Delage G, Long A, Thibault L, Robillard P. Allergic transfusion reactions from blood components donated by IgA-deficient donors with and without anti-IgA: a comparative retrospective study. Vox Sang (2010) 99:136-41. doi:10.1111/j.1423-0410.2010.01326.x
44. Horn J, Thon V, Bartonkova D, Salzer U, Warnatz K, Schlesier M, et al. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin Immunol (2007) 122:156-62. doi:10.1016/j.clim.2006.10.002
45. Sundin U, Nava S, Hammarström L. Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol (1998) 112:341-6. doi:10.1046/j.1365-2249.1998.00571.x
46. van der Heijden J, Geissler J, van Mirre E, van Deuren M, van der Meer JWM, Salama A, et al. A novel splice variant of FcgRIIa: a risk factor for anaphylaxis in patients with hypogammaglobulinemia. J Allergy Clin Immunol (2013) 131:1408.e-16.e. doi:10.1016/j.jaci.2013.02.009
47. Aukrust P, Frøland SS, Liabakk NB, Müller F, Nordoy I, Haug C, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood (1994) 84:2136-43.
48. Berkovitch M, Dolinski G, Tauber T, Aladjem M, Kaplinsky C. Neutropenia as a complication of intravenous immunoglobulin (IVIG) therapy in children with immune thrombocytopenic purpura: common and non-alarming. Int J Immunopharmacol (1999) 21:411-5. doi:10.1016/S0192-0561(99)00020-X
49. Bolli R, Brügger R, Hodler G, Maeder W, Spycher MO, Gennari K. IgG dimers in liquid intravenous immunoglobulin preparations. In: Kazatchkine MD, Morell A, editors. Intravenous Immunoglobulin-Research and Therapy. London: The Parthenon Publishing Group (1996). p. 307-8.
50. Schnorf J, Arnet B, Burek-Kozlowska A, Gennari K, Rohner R, Späth PJ, et al. Laboratory parameters measured during infusion of immunoglobulin preparations for intravenous use and related tolerability. In: Kazatchkine MD, Morell A, editors. Intravenous Immunoglobulin-Research and Therapy. London: The Parthenon Publishing Group (1996). p. 312-3.
51. Spycher MO, Bolli R, Hodler G, Gennari K, Hubsch A, Späth P, et al. Well-tolerated liquid intravenous immunoglobulin G preparations (IVGG) have a low immunoglobulin G dimer (IgG-dimer) content. J Autoimmun (1999) 96(Suppl 1):S96A.
52. Bleeker WK, Agterberg J, Rigter G, de Vries van Rosen A, Bakker JC. An animal model for the detection of hypotensive side effects of immunoglobulin preparations. Vox Sang (1987) 52:281-90. doi:10.1111/j.1423-0410.1987.tb04894.x
53. Bleeker WK, Agterberg J, Rigter G, Van Rooijen N, Bakker JC. Key role of macrophages in hypotensive side effects of immunoglobulin preparations. Studies in an animal model. Clin Exp Immunol (1989) 77:338-44.
54. Bleeker WK, Teeling JL, Verhoeven AJ, Rigter GM, Agterberg J, Tool AT, et al. Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase. Blood (2000) 95:1856-61.
55. Teeling JL, Bleeker WK, Rigter GM, Van Rooijen N, Kuijpers TW, Hack CE. Intravenous immunoglobulin preparations induce mild activation of neutrophils in vivo via triggering of macrophages-studies in a rat model. Br J Haematol (2001) 112:1031-40. doi:10.1046/j.1365-2141.2001.02674.x
56. Kroez M, Kanzy EJ, Gronski P, Dickneite G. Hypotension with intravenous immunoglobulin therapy: importance of pH and dimer formation. Biologicals (2003) 31:277-86. doi:10.1016/j.biologicals.2003.09.001
57. Teeling JL, Jansen-Hendriks T, Kuijpers TW, De Haas M, van de Winkel JG, Hack CE, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood (2001) 98:1095-9. doi:10.1182/blood.V98.4.1095
58. Farber CM, Crusiaux A, Schandene L, Van Vooren JP, Goldman M, Dupont E, et al. Tumor necrosis factor and intravenous gammaglobulins in common variable immunodeficiency. Clin Immunol Immunopathol (1994) 72:233-6. doi:10.1006/clin.1994.1136
59. Bagdasarian A, Tonetta S, Harel W, Mamidi R, Uemura Y. IVIG adverse reactions: potential role of cytokines and vasoactive substances. Vox Sang (1998) 74:74-82. doi:10.1046/j.1423-0410.1998.7420074.x
60. Michelis FV, Branch DR, Scovell I, Bloch E, Pendergrast J, Lipton JH, et al. Acute hemolysis after intravenous immunoglobulin amid host factors of ABO-mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes. Transfusion (2014) 54:681-90. doi:10.1111/trf.12329
61. Ling ZD, Yeoh E, Webb BT, Farrell K, Doucette J, Matheson DS. Intravenous immunoglobulin induces interferon-γ and interleukin-6 in vivo. J Clin Immunol (1993) 13:302-9. doi:10.1007/BF00920238
62. Yoo EM, Wims LA, Chan LA, Morrison SL. Human IgG2 can form covalent dimers. J Immunol (2003) 170:3134-8. doi:10.4049/jimmunol.170.6.3134
63. Vassilev TL, Bineva IL, Dietrich G, Kaveri SV, Kazatchkine MD. Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies. J Autoimmun (1995) 8:405-13. doi:10.1006/jaut.1995.0032
64. Simon HU, Späth PJ. IVIG-mechanisms of action. Allergy (2003) 58:543-52. doi:10.1034/j.1398-9995.2003.00239.x
65. Gronski P. IgG dimers in multidonor-derived immunoglobulins: aspects of generation and function. Curr Pharm Des (2006) 12:181-90. doi:10.2174/138161206775193154
66. Tankersley DL, Preston MS, Finlayson JS. Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol Immunol (1988) 25:41-8. doi:10.1016/0161-5890(88)90088-0
67. Roux KH, Tankersley DL. A view of the human idiotypic repertoire-electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol (1990) 144:1387-95.
68. Gronski P, Schridde C, Forsterling HD. Polyreactive antibodies in multidonor-derived immunoglobulin G: theory and conclusions drawn from experiments. Immunobiology (2010) 215:356-69. doi:10.1016/j.imbio.2009.06.015
69. Miescher SM, Schaub A, Ghielmetti M, Baumann M, Vogel M, Bolli R, et al. Comparative analysis of antigen specificities in the monomeric and dimeric fractions of intravenous immunoglobulin. Ann N Y Acad Sci (2005) 1051:582-90. doi:10.1196/annals.1361.102
70. Wymann S, Ghielmetti M, Schaub A, Baumann MJ, Stadler BM, Bolli R, et al. Monomerization of dimeric IgG of intravenous immunoglobulin (IVIg) increases the antibody reactivity against intracellular antigens. Mol Immunol (2008) 45:2621-8. doi:10.1016/j.molimm.2007.12.020
71. Relkin NR, Szabo P, Rotondi M, Mujalli D. Antibodies in the dimer fraction of IVIg have the capacity to bind beta amyloid. Alzheimers Dement (2009) 5:427-8. doi:10.1016/j.jalz.2009.04.959
72. Schaub A, von Gunten S, Vogel M, Wymann S, Stadler B, Spycher M, et al. An analysis of anti-Fas and anti-Siglec-9 autoantibodies in monomeric and dimeric fractions of IVIG. Allergy (2009) 64:268-9. doi:10.1111/j.1398-9995.2011.02579.x
73. Schaub A, von Gunten S, Vogel M, Wymann S, Rüegsegger M, Stadler BM, et al. Dimeric IVIG contains natural anti-Siglec-9 autoantibodies and their anti-idiotypes. Allergy (2011) 66:1030-7. doi:10.1111/j.1398-9995.2011.02579.x
74. Bridgham M, Drake M, Maguire K. A case of haemolysis following administration of intravenous immunoglobulin [abstract]. Transfus Med (2014) 24:58. doi:10.1111/tme.12139
75. Clemenz MR, Joseph WM, Shuler MJ, Lynn AW. Intravenous immunoglobulin-induced hemolytic anemia in a patient with juvenile dermatomyositis. J Drugs Dermatol (2013) 12:111-3.
76. Desborough MJ, Miller J, Thorpe SJ, Murphy MF, Misbah SA. Intravenous immunoglobulin-induced haemolysis: a case report and review of the literature. Transfus Med (2013) 24:219-26. doi:10.1111/tme.12083
77. Mohamed M, Bates G, Eastley B. Massive intravascular haemolysis after high dose intravenous immunoglobulin therapy. Br J Haematol (2013) 160:570. doi:10.1111/bjh.12182
78. Rink BD, Gonik B, Chmait RH, O'Shaughnessy R. Maternal hemolysis after intravenous immunoglobulin treatment in fetal and neonatal alloimmune thrombocytopenia. Obstet Gynecol (2013) 121:471-3. doi:10.1097/AOG.0b013e3182765c63
79. Berard R, Whittemore B, Scuccimarri R. Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases. Pediatr Rheumatol Online J (2012) 10:10. doi:10.1186/1546-0096-10-10
80. Pintova S, Bhardwaj AS, Aledort LM. IVIG-a hemolytic culprit. N Engl J Med (2012) 367:974-6. doi:10.1056/NEJMc1205644
81. Morgan S, Sorensen P, Vercellotti G, Zantek ND. Haemolysis after treatment with intravenous immunoglobulin due to anti-A. Transfus Med (2011) 21:267-70. doi:10.1111/j.1365-3148.2011.01078.x
82. Welles CC, Tambra S, Lafayette RA. Hemoglobinuria and acute kidney injury requiring hemodialysis following intravenous immunoglobulin infusion. Am J Kidney Dis (2010) 55:148-51. doi:10.1053/j.ajkd.2009.06.013
83. Canadian Blood Services. Important Information Regarding IVIG Associated Hemolysis (2014). Available from: http://www.bloodservices.ca/CentreApps/Internet/UW_V502_MainEngine.nsf/resources/CustomerLetters09/$file/CL_2009-02.pdf
84. Gordon DJ, Sloan SR, de Jong JL. A pediatric case series of acute hemolysis after administration of intravenous immunoglobulin. Am J Hematol (2009) 84:771-2. doi:10.1002/ajh.21544
85. Kahwaji J, Barker E, Pepkowitz S, Klapper E, Villicana R, Peng A, et al. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol (2009) 4:1993-7. doi:10.2215/CJN.04540709
86. Daw Z, Padmore R, Neurath D, Cober N, Tokessy M, Desjardins D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion (2008) 48:1598-601. doi:10.1111/j.1537-2995.2008.01721.x
87. Yin F, Nesbitt JA, Tobian AA, Holt PA, Mikdashi J. Hemolytic anemia following intravenous immunoglobulin administration. Am J Hematol (2008) 83:825. doi:10.1002/ajh.21263
88. Coghill J, Comeau T, Shea T, Braddy L, Bandarenko N, Afenyi-Annan A, et al. Acute hemolysis in a patient with cytomegalovirus pneumonitis treated with intravenous immunoglobulin (IVIG). Biol Blood Marrow Transplant (2006) 12:786-8. doi:10.1016/j.bbmt.2006.03.003
89. Singh-Grewal D, Kemp A, Wong M. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions. Arch Dis Child (2006) 91:651-4. doi:10.1136/adc.2005.078733
90. Chamouni P, Tamion F, Gueit I, Girault C, Lenain P, Varin R, et al. Adverse effect of polyvalent immunoglobulin in the treatment of Guillain-Barré syndrome. Transfus Apher Sci (2003) 28:117-24. doi:10.1016/S1473-0502(03)00012-0
91. Karaaslan S, Oran B, Calisman Ü, Baysal T, Baspinar O, Tas A. Hemolysis after administration of high-dose immunoglobulin in a patient with myocarditis. Turk J Haematol (2003) 20:237-40.
92. Trifa M, Simon L, Hamza J, Bavoux F, des Roziers NB. Haemolytic anaemia associated with high dose intravenous immunoglobulin therapy in a child with Guillain-Barré syndrome. Arch Dis Child (2003) 88:836-7. doi:10.1136/adc.88.9.836-b
93. Ballot-Brossier C, Mortelecque R, Sinegre M, Marceau A, Dauriat G, Courtois F. Insisting on intravenous polyvalent immunoglobulin therapy in polymyositis in spite of the occurrence of sever hemolytic anemia-poursuite du traitement d'une polymyosite par les immunoglobulines intraveineuses polyvalentes malgré la survenue d'une anémie hémolytique sévère. Transfus Clin Biol (2001) 8:94-9.
94. Nagakawa M, Watanabe N, Okuno M, Kondo M, Okagawa H, Taga T. Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki disease. Am J Hematol (2000) 63:160-1. doi:10.1002/(SICI)1096-8652(200003)63:3<160::AID-AJH11>3.0.CO;2-4
95. Wilson JR, Bhoopalam H, Fisher M. Hemolytic anemia associated with intravenous immunoglobulin. Muscle Nerve (1997) 20:1142-5. doi:10.1002/(SICI)1097-4598(199709)20:9<1142::AID-MUS8>3.0.CO;2-8
96. Munoz J, Garcia A, Jordan C, Rubio A, Ferran C, Martinez Matos JA. Hemolysis during immunoglobulin therapy-hemolisis durante el tratamiento con inmunoglobulinas. Sangre (Barc) (1996) 41:72-3.
97. Tamada K, Kohga M, Masuda H, Hattori K. Hemolytic anemia following high-dose intravenous immunoglobulin administration. Acta Paediatr Jpn (1995) 37:391-3. doi:10.1111/j.1442-200X.1995.tb03339.x
98. Boothe G, Brecher ME, Root M, Robinson J, Haley R. Acute hemolysis due to passively transfused high-titer anti-B causing spontaneous in vitro agglutination. Immunohematology (1995) 11:43-5.
99. Thomas MJ, Misbah SA, Chapel HM, Jones M, Elrington G, Newsom-Davis J. Hemolysis after high-dose intravenous Ig. Blood (1993) 82:3789.
100. Comenzo RL, Malachowski ME, Meissner HC, Fulton DR, Berkman EM. Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of IVIG for Kawasaki disease. J Pediatr (1992) 120:926-8. doi:10.1016/S0022-3476(05)81964-X
101. Rovelli A, D'Angelo P, Balduzzi A, Borzini P, Biondi A, Uderzo C. Acute intravascular haemolysis associated with high dose immunoglobulin after bone marrow transplantation for acute myelogenous leukemia. Leuk Lymphoma (1991) 5:71-4. doi:10.3109/10428199109068107
102. Okubo S, Ishida T, Yasunaga K. Hemolysis after intravenous immune globulin therapy: relation to IgG subclasses of red cell antibody. Transfusion (1990) 30:436-8. doi:10.1046/j.1537-2995.1990.30590296378.x
103. Hillyer CD, Schwenn MR, Fulton DR, Meissner HC, Berkman EM. Autoimmune hemolytic anemia in Kawasaki disease: a case report. Transfusion (1990) 30:738-40. doi:10.1046/j.1537-2995.1990.30891020336.x
104. Nicholls MD, Cummins JC, Davies VJ, Greenwood JK. Haemolysis induced by intravenously-administered immunoglobulin. Med J Aust (1989) 150:404-6.
105. Kim HC, Park CL, Cowan JH III, Fattori FD, August CS. Massive intravascular hemolysis associated with intravenous immunoglobulin in bone marrow transplant recipients. Am J Pediatr Hematol Oncol (1988) 10:69-74. doi:10.1097/00043426-198821000-00012
106. Brox AG, Cournoyer D, Sternbach M, Spurll G. Hemolytic anemia following intravenous gamma globulin administration. Am J Med (1987) 82:633-5. doi:10.1016/0002-9343(87)90112-4
107. Copelan EA, Strohm PL, Kennedy MS, Tutschka PJ. Hemolysis following intravenous immune globulin therapy. Transfusion (1986) 26:410-2. doi:10.1046/j.1537-2995.1986.26587020113.x
108. Atrah HI, Crawford RJ, Templeton JG, Carlyle JE. Transient haemoglobin drop following high dose intravenous immunoglobulin. Clin Lab Haematol (1985) 7:283. doi:10.1111/j.1365-2257.1985.tb00038.x
109. Kessary-Shoham H, Levy Y, Shoenfeld Y, Lorber M, Gershon H. In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. J Autoimmun (1999) 13:129-35. doi:10.1006/jaut.1999.0302
110. Quinti I, Pulvirenti F, Milito C, Granata G, La Marra F, Farrugia A, et al. Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment. Transfusion (2014). doi:10.1111/trf.12939
111. Thorpe SJ, Fox BJ, Dolman CD, Lawrence J, Thorpe R. Batches of intravenous immunoglobulin associated with adverse reactions in recipients contain atypically high anti-Rh D activity. Vox Sang (2003) 85:80-4. doi:10.1046/j.1423-0410.2003.00336.x
112. Baxley A, Akhtari M. Hematologic toxicities associated with intravenous immunoglobulin therapy. Int Immunopharmacol (2011) 11:1663-7. doi:10.1016/j.intimp.2011.07.024
113. Thorpe SJ, Fox BJ, Dolman CD, Thorpe R. Anti-A and anti-B activity in batches of different intravenous immunoglobulin products determined using a direct haemagglutination method. Biologicals (2005) 33:111-6. doi:10.1016/j.biologicals.2005.02.002
114. Thorpe SJ, Fox B, Sharp G, Virata ML, Yu MW, Thorpe R. International collaborative study to evaluate candidate reference reagents to standardize haemagglutination testing for anti-A and anti-B in normal intravenous immunoglobulin products. Vox Sang (2009) 97:160-8. doi:10.1111/j.1423-0410.2009.01194.x
115. European Directorate for the Quality of Medicines and Healthcare. Human Normal Immunoglobulin for Intravenous Administration. 7th Monograph 0918 ed. European Pharmacopoeia. Strasbourg: Council of Europe (2011). p. 4166-8.
116. European Directorate for the Quality of Medicines and Healthcare. Anti-A and Anti-B Haemagglutinins. 7th General Chapter 2.6.20 ed. European Pharmacopoeia. Strasbourg: Council of Europe (2011).
117. European Directorate for the Quality of Medicines and Healthcare. Test for Anti-D Antibodies in Human Immunoglobulin. 7th General Chapter 2.6.26 ed. European Pharmacopoeia. Strasbourg: Council of Europe (2011). 3546 p.
118. Shoham-Kessary H, Naot Y, Gershon H. Immune complex-like moieties in immunoglobulin for intravenous use (i.v.Ig) bind complement and enhance phagocytosis of human erythrocytes. Clin Exp Immunol (1998) 113:77-84. doi:10.1046/j.1365-2249.1998.00624.x
119. Hudson KE, Lin E, Hendrickson JE, Lukacher AE, Zimring JC. Regulation of primary alloantibody response through antecedent exposure to a microbial T-cell epitope. Blood (2010) 115:3989-96. doi:10.1182/blood-2009-08-238568
120. Rodeghiero F, Schiavotto C, Castaman G, Vespignani M, Ruggeri M, Dini E. A follow-up study of 49 adult patients with idiopathic thrombocytopenic purpura treated with high-dose immunoglobulins and anti-D immunoglobulins. Haematologica (1992) 77:248-52.
121. Padmore RF. Hemolysis upon intravenous immunoglobulin transfusion. Transfus Apher Sci (2012) 46:93-6. doi:10.1016/j.transci.2011.11.004
122. Report of the FDA meeting on Strategies to address Hemolytic complications of Immune Globulin Infusions. Washington, DC: US FDA (2014).
123. Sewell WA, Kerr J, Behr-Gross ME, Peter HH, Kreuth Ig Working Group. European consensus proposal for immunoglobulin therapies. Eur J Immunol (2014) 44:2207-14. doi:10.1002/eji.201444700
124. Jacobson NM. The art of balanced production. In: Valverde JL, editor. Pharmaceuticals Policy and Law-Blood, Plasma and Plasma Proteins: A Unique Contribution to Modern Healthcare (Vol. 7), Amsterdam, NL: IOS Press (2006). p. 81-7.
125. Dhainaut F, Guillaumat PO, Dib H, Perret G, Sauger A, De Coupade C, et al. In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations. Vox Sang (2013) 104:115-26. doi:10.1111/j.1423-0410.2012.01648.x
126. Roch B, Monrepos S, Dhainaut F, Milchaski C, De Coupade C, Sauger A, et al. Patient safety through an IVIg mastered manufacturing process. Posters. European Symposium Proceedings. European Directorate for the Quality of Medicines & HealthCare (2013). p. 1-351. Available from: https://www.edqm.eu/medias/fichiers/posters_kreuth_iii.pdf
127. Siani B, Willimann K, Wymann S, Marques AA, Widmer E. Isoagglutinin reduction in human immunoglobulin products by donor screening. Biol Ther (2014) 4:15-26. doi:10.1007/s13554-014-0016-2
128. Höfferer L. IgG product development isoagglutinin reduction measures. Oral presentation, International Plasma Protein Congress. Vienna: Plasma Protein Therapeutics Association (2014).
129. Späth PJ, Lutz HU. Naturally occurring antibodies/autoantibodies in polyclonal immunoglobulin concentrates. Lutz, H. U. Naturally Occurring Antibodies (NAbs). Adv Exp Med Biol (2012) 750:239-61. doi:10.1007/978-1-4614-3461-0_18
130. Lutz HU, Bussolino BF, Flepp R, Fasler S, Stammler P, Kazatchkine MD, et al. Naturally occurring anti-band-3 antibodies and complement together mediate phagocytosis of oxidatively stressed human erythrocytes. Proc Natl Acad Sci USA (1987) 84:7368-72. doi:10.1073/pnas.84.21.7368
131. Lutz HU, Stammler P, Jelezarova E, Nater M, Späth PJ. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood (1996) 88:184-93.
132. Lutz HU, Stammler P, Bianchi V, Trüeb RM, Hunziker T, Burger R. Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood (2004) 103:465-72. doi:10.1182/blood-2003-05-1530
133. Nydegger UE, Tevaearai H, Berdat P, Rieben R, Carrel T, Mohacsi P, et al. Histo-blood group antigens as allo-and autoantigens. Ann N Y Acad Sci (2005) 1050:40-51. doi:10.1196/annals.1313.006
134. Springer GF, Horton RE. Blood group isoantibody stimulation in man by feeding blood group-active bacteria. J Clin Invest (1969) 48:1280-91. doi:10.1172/JCI106094
135. Spalter SH, Kaveri SV, Bonnin E, Mani JC, Cartron JP, Kazatchkine MD. Normal human serum contains natural antibodies reactive with autologous AB0 blood group antigens. Blood (1999) 93:4418-24.
136. Galili U, Rachmilewitz EA, Peleg A, Flechner I. A unique natural human IgG antibody with anti-alpha-galactosyl specificity. J Exp Med (1984) 160:1519-31. doi:10.1084/jem.160.5.1519
137. Obukhova P, Rieben R, Bovin N. Normal human serum contains high levels of anti-Gala1-4GlcNAc antibodies. Xenotransplantation (2007) 14:627-35. doi:10.1111/j.1399-3089.2007.00436.x
138. Obukhova P, Korchagina E, Henry S, Bovin N. Natural anti-A and anti-B of the AB0 system: allo-and autoantibodies have different epitope specificity. Transfusion (2012) 52:860-9. doi:10.1111/j.1537-2995.2011.03381.x
139. Bovin N, Bovin N, Obukhova P, Shilova N, Rapoport E, Popova I, et al. Repertoire of human natural anti-glycan immunoglobulins. Do we have auto-antibodies? Biochim Biophys Acta (2012) 1820:1373-82. doi:10.1016/j.bbagen.2012.02.005
140. Galili U, Mandrell RE, Hamadeh RM, Shohet SB, McLeod Griffiss J. Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun (1988) 56:1730-7.
141. Lutz HU. Innate immune and non-immune mediators of erythrocyte clearance. Cell Mol Biol (Noisy-le-Grand) (2004) 50:107-16.
142. Sorette MP, Galili U, Clark MR. Comparison of serum anti-band 3 and anti-Gal antibody binding to density-separated human red blood cells. Blood (1991) 77:628-36.
143. Wieslander J, Mansson O, Kallin E, Gabrielli A, Nowack H, Timple R. Specificity of human antibodies against gala1-3gal carbohydrate epitope and distinction from natural antibodies reacting with gala1-2gal or gala1-4 gal. Glycoconj J (1990) 7:85-100. doi:10.1007/BF01050405
144. Nardini C. Anti-A and anti-B haemagglutinin trend analysis during manufacturing process of IVIG. Presentation at Workshop "Strategies to Address Hemolytic Complications of Immune Globulin Infusions". Washington, DC: US FDA (2014).
145. Rieben R, Korchagina EY, von Allmen E, Hovinga JK, Lämmle B, Jungi TW. In vitro evaluation of the efficacy and biocompatibility of new, synthetic AB0 immunoabsorbents. Transplantation (1995) 60:425-30. doi:10.1097/00007890-199509000-00004
146. Alikhani A, Korchagina EY, Chinarev AA, Bovin NV, Federspiel WJ. High molecular weight blood group A trisaccharide-polyacrylamide glycoconjugates as synthetic blood group A antigens for anti-A antibody removal devices. J Biomed Mater Res B Appl Biomater (2009) 91:845-54. doi:10.1002/jbm.b.31466
147. Gautam S, Korchagina EY, Bovin NV, Federspiel WJ. Specific antibody filter (SAF) binding capacity enhancement to remove anti-A antibodies. J Biomed Mater Res B Appl Biomater (2010) 95:475-80. doi:10.1002/jbm.b.31707
148. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol (2005) 29:173-84. doi:10.1385/CRIAI:29:3:173
149. Rajabally YA, Kearney DA. Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study. J Neurol Sci (2011) 308:124-7. doi:10.1016/j.jns.2011.05.035
150. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology (1994) 44:223-6. doi:10.1212/WNL.44.2.223
151. Sakem B, Matozan K, Nydegger UE, Weigel G, Griesmacher A, Risch L. Anti-red blood cell antibodies, free light chains, and antiphospholipid antibodies in intravenous immunoglobulin preparations. Isr Med Assoc J (2013) 15:617-21.
152. Grosse-Wilde H, Blasczyk R, Westhoff U. Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations. Tissue Antigens (1992) 39:74-7. doi:10.1111/j.1399-0039.1992.tb01910.x
153. Sztajzel R, Le Floch-Rohr J, Eggimann P. High-dose intravenous immunoglobulin treatment and cerebral vasospasm: a possible mechanism of ischemic encephalopathy? Eur Neurol (1999) 41:153-8. doi:10.1159/000008040
154. Vinod KV, Kumar M, Nisar KK. High dose intravenous immunoglobulin may be complicated by myocardial infarction. Indian J Crit Care Med (2014) 18:247-9. doi:10.4103/0972-5229.130579
155. Iroh Tam PY, Richardson M, Grewal S. Fatal case of bilateral internal jugular vein thrombosis following IVIg infusion in an adolescent girl treated for ITP. Am J Hematol (2008) 83:323-5. doi:10.1002/ajh.21107
156. Al-Riyami AZ, Lee J, Connolly M, Shereck E. Cerebral sinus thrombosis following IV immunoglobulin therapy of immune thrombocytopenia purpura. Pediatr Blood Cancer (2011) 57:157-9. doi:10.1002/pbc.22968
157. Sin YH, Kim YJ, Oh JS, Lee JH, Kim SM, Kim JK. Graft rupture after high-dose intravenous immunoglobulin therapy in a renal transplant patient. Nephrology (2014) 19:35-6. doi:10.1111/nep.12248
158. Barada W, Muwakkit S, Hourani R, Bitar M, Mikati M. Cerebral sinus thrombosis in a patient with humoral immunodeficiency on intravenous immunoglobulin therapy: a case report. Neuropediatrics (2008) 39:131-3. doi:10.1055/s-2008-1077088
159. Lee YJ, Shin JU, Lee J, Kim K, Kim WS, Ahn JS, et al. A case of deep vein thrombosis and pulmonary thromboembolism after intravenous immunoglobulin therapy. J Korean Med Sci (2007) 22:758-61. doi:10.3346/jkms.2007.22.4.758
160. White DA, Leonard MC. Acute stroke with high-dose intravenous immune globulin. Am J Health Syst Pharm (2007) 64:1611-4. doi:10.2146/ajhp060205
161. Feuillet L, Milandre L, Ali Cherif A. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis (2006) 17:85. doi:10.1097/01.mbc.0000194367.37721.a5
162. Marie I, Hervé F, Kerleau JM, Maurey G, Levesque H. Intravenous immunoglobulin-associated vena cava thrombosis. Thromb Haemost (2006) 96:849-51. doi:10.1160/TH06-09-0503
163. Marie I, Maurey G, Hervé F, Hellot MF, Levesque H. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol (2006) 155:714-21. doi:10.1111/j.1365-2133.2006.07390.x
164. Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature. Ann Hematol (2004) 83:661-5. doi:10.1007/s00277-004-0895-2
165. Geller JL, Hackner D. Diffuse venous thromboemboli associated with IVIg therapy in the treatment of streptococcal toxic shock syndrome: case report and review. Ann Hematol (2005) 84:601-4. doi:10.1007/s00277-005-1043-3
166. Feuillet L, Guedj E, Laksiri N, Philip E, Habib G, Pelletier J, et al. Deep vein thrombosis after intravenous immunoglobulins associated with methylprednisolone. Thromb Haemost (2004) 92:662-5.
167. Sheehan DJ, Lesher JL. Deep venous thrombosis after high-dose intravenous immunoglobulin in the treatment of pemphigus vulgaris. Cutis (2004) 73:403-6.
168. Vucic S, Chong PS, Dawson KT, Cudkowicz M, Cros D Jr. Thromboembolic complications of intravenous immunoglobulin treatment. Eur Neurol (2004) 52:141-4. doi:10.1159/000081465
169. Stamboulis E, Theodorou V, Kilidireas K, Apostolou T. Acute myocardial infarction following intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy in association with a monoclonal immunoglobulin G paraprotein. Eur Neurol (2004) 51:51. doi:10.1159/000075091
170. Katz KA, Hivnor CM, Geist DE, Shapiro M, Ming ME, Werth VP. Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions. Arch Dermatol (2003) 139:991-3. doi:10.1001/archderm.139.8.991
171. Zaidan R, Al Moallem M, Wani BA, Shameena AR, Al Tahan AR, Daif AK, et al. Thrombosis complicating high dose intravenous immunoglobulin: report of three cases and review of the literature. Eur J Neurol (2003) 10:367-72. doi:10.1046/j.1468-1331.2003.00542.x
172. Brown HC, Ballas ZK. Acute thromboembolic events associated with intravenous immunoglobulin infusion in antibody-deficient patients. J Allergy Clin Immunol (2003) 112:797-9. doi:10.1016/S0091-6749(03)01780-9
173. Evangelou N, Littlewood T, Anslow P, Chapel H. Transverse sinus thrombosis and IVIg treatment: a case report and discussion of risk-benefit assessment for immunoglobulin treatment. J Clin Pathol (2003) 56:308-9. doi:10.1136/jcp.56.4.308
174. Emerson GG, Herndon CN, Sreih AG. Thrombotic complications after intravenous immunoglobulin therapy in two patients. Pharmacotherapy (2002) 22:1638-41. doi:10.1592/phco.22.17.1638.34125
175. Alliot C, Rapin JP, Besson M, Bedjaoui F, Messouak D. Pulmonary embolism after intravenous immunoglobulin. J R Soc Med (2001) 94:187-8.
176. Sherer Y, Levy Y, Langevitz P, Rauova L, Fabrizzi F, Shoenfeld Y. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology (2001) 62:133-7. doi:10.1159/000056085
177. Elkayam O, Paran D, Milo R, Davidovitz Y, Almoznino-Sarafian D, Zeltser D, et al. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases. Ann Rheum Dis (2000) 59:77-80. doi:10.1136/ard.59.1.77
178. Go RS, Call TG. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc (2000) 75:83-5. doi:10.4065/75.1.83
179. Turner B, Wills AJ. Cerebral infarction complicating intravenous immunoglobulin therapy in a patient with Miller Fisher syndrome. J Neurol Neurosurg Psychiatry (2000) 68:790-1. doi:10.1136/jnnp.68.6.790
180. Harkness KA, Goulding P. Central retinal vein occlusion complicating treatment with intravenous immunoglobulin. Eye (Lond) (2000) 14:662-3. doi:10.1038/eye.2000.163
181. Paolini R, Fabris F, Cella G. Acute myocardial infarction during treatment with intravenous immunoglobulin for idiopathic thrombocytopenic purpura (ITP). Am J Hematol (2000) 65:177-8. doi:10.1002/1096-8652(200010)65:2<177::AID-AJH17>3.0.CO;2-K
182. Rosenbaum JT. Myocardial infarction as a complication of immunoglobulin therapy. Arthritis Rheum (1997) 40:1732-3. doi:10.1002/art.38
183. Oh KT, Boldt HC, Danis RP. Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration. Am J Ophthalmol (1997) 124:416-8. doi:10.1016/S0002-9394(14)70844-X